Compare AEO & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | BLCO |
|---|---|---|
| Founded | 1977 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.4B |
| IPO Year | 2004 | 2022 |
| Metric | AEO | BLCO |
|---|---|---|
| Price | $17.86 | $16.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $21.09 | $18.45 |
| AVG Volume (30 Days) | ★ 5.6M | 426.6K |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $5,547,236,000.00 | $5,101,000,000.00 |
| Revenue This Year | $5.22 | $8.65 |
| Revenue Next Year | $3.38 | $5.59 |
| P/E Ratio | $128.86 | ★ N/A |
| Revenue Growth | 4.10 | ★ 6.47 |
| 52 Week Low | $9.56 | $12.41 |
| 52 Week High | $28.46 | $18.92 |
| Indicator | AEO | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 63.89 |
| Support Level | $17.05 | $14.62 |
| Resistance Level | $18.14 | $16.54 |
| Average True Range (ATR) | 0.88 | 0.43 |
| MACD | 0.06 | 0.14 |
| Stochastic Oscillator | 50.52 | 77.94 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.